Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

1,050

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

April 8, 2021

Study Completion Date

September 8, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

batch 1 of Ad5-nCoV

The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101001. It contains 5×10\^10 viral particles per 0.5 mL in a vial.

BIOLOGICAL

batch 2 of Ad5-nCoV

The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202101002. It contains 5×10\^10 viral particles per 0.5 mL in a vial.

BIOLOGICAL

batch 3 of Ad5-nCoV

The vaccine is a replication defective Ad5 vectored vaccine expressing the full-length spike glycoprotein of SARS-CoV-2 produced by CanSino, lot NCOV202102003. It contains 5×10\^10 viral particles per 0.5 mL in a vial.

Trial Locations (1)

222000

Guanyun Center for Disease Control and Prevention, Lianyungang

All Listed Sponsors
lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT05313646 - Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy Adults | Biotech Hunter | Biotech Hunter